https://sms.carm.es/ricsmur/handle/123456789/17624 2026-05-27T10:05:40Z 2026-05-27T10:05:40Z Terres-Jiménez, Belén Domínguez-Cabanero, Elena-M González-Vivas, Carlos García-Parreno, Beatriz Diego-Castano, Sara Gesler, Mika-Aiko de-Entrambasaguas, Manuel Lorente-Rovira, Esther https://sms.carm.es/ricsmur/handle/123456789/26527 2026-05-13T11:04:54Z 2022-09-01T00:00:00Z

Variables asociadas al éxito de la terapia cognitivo conductual grupal para el insomnio: resultados preliminares Terres-Jiménez, Belén; Domínguez-Cabanero, Elena-M; González-Vivas, Carlos; García-Parreno, Beatriz; Diego-Castano, Sara; Gesler, Mika-Aiko; de-Entrambasaguas, Manuel; Lorente-Rovira, Esther Insomnia Disorder (ID) is defined as the predominant dissatisfaction with the quantity or quality of sleep associated with difficulty in initiating or maintaining sleep or early-morning awakenings with the inability to go back to sleep.

2022-09-01T00:00:00Z Pastor-Cano, Josep Aranda-García, Ana Gascón-Cánovas, Juan-José Rausell-Rausell, Víctor-José Tobaruela-Soto, Mariana https://sms.carm.es/ricsmur/handle/123456789/26521 2026-05-13T11:04:53Z 2017-01-01T00:00:00Z

Criterios Beers versus STOPP. Posibles implicaciones de la adaptación española de los criterios de Beers Pastor-Cano, Josep; Aranda-García, Ana; Gascón-Cánovas, Juan-José; Rausell-Rausell, Víctor-José; Tobaruela-Soto, Mariana

2017-01-01T00:00:00Z Pacheco-López, Pilar Meroño-Saura, María-Antonia Aranda-García, Ana https://sms.carm.es/ricsmur/handle/123456789/26518 2026-05-13T11:04:49Z 2021-01-01T00:00:00Z

Uso de Ataluren en españa: incoherencias administrativas y aspectos éticos implicados Pacheco-López, Pilar; Meroño-Saura, María-Antonia; Aranda-García, Ana Duchenne muscular dystrophy is a rare genetic disease with only ataluren like pharmaceutical treatment available. This drug received a conditional authorization by the European Medicines Agency (EMA) in 2014, meaning that it was commercially available while waiting for more solid results that demonstrate the efficacy and safety. Currently, the authorization still maintains the "conditional" modality, and the actual health benefits of the drug still remain unclear. In Spain, ataluren is not financed by the National Health System. The decision of non-financing has generated a heated debate, especially because in those patients who se treatment were started prior to the non-financing decision the drug has continued being funded. This controversial situation encompasses complex aspects of pharmaceutical and health management related to scientific evidence, the motivations of regulatory agencies and the pharmaceutical industry in the processes of drug investigation and authorization. Furthermore, as the center of the debate, some pillars of bioethics such as justice and equity, as well as certain legal principles, such as the protection of minors, are involved.

2021-01-01T00:00:00Z Salas-Valero, Montserrat Aguinaga-Ontoso, Enrique Castellote, María-Jesús Gaminde, Idoia Juan-Quilis, Verónica Páez-Cervi, Virgili Revilla-López, Elena Roqué-Castellà, Pilar Serrano-Aguilar, Pedro https://sms.carm.es/ricsmur/handle/123456789/26244 2026-04-30T07:45:18Z 2019-05-01T00:00:00Z

REBISALUD: la red de bibliotecas virtuales de salud Salas-Valero, Montserrat; Aguinaga-Ontoso, Enrique; Castellote, María-Jesús; Gaminde, Idoia; Juan-Quilis, Verónica; Páez-Cervi, Virgili; Revilla-López, Elena; Roqué-Castellà, Pilar; Serrano-Aguilar, Pedro

2019-05-01T00:00:00Z